ARBE Earnings

ARBE reported its FY2025Q3 earnings on 2025-11-17, showcasing a revenue of 254.00K against an estimate of 615.00K, resulting in a -58.68% surprise. The EPS was -0.1, surpassing the expected -0.07 by -42.86% . The stock experienced a -10.34% price change on the earnings day and a -11.03% change over the next five days, reflecting market reactions to the results.

Following ARBE's FY2025Q3 earnings announcement on 2025-11-17, the stock price moved by -10.34% on the day of the release. Over the subsequent five days, it saw a -11.03% change. Historically, ARBE's stock price tends to shift by an average of +14.13% in the 10 days leading up to earnings and +6.00% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ARBE’s annual revenue to reach 722.00K, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -50.85% and EPS estimates Revise Downward by -60.74% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ARBE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -50.85%, while EPS estimates moved Revise Downward by -60.74% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARBE's stock price typically moves by +14.13% in the 10 days before its earnings and +6.00% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 722.00K.

The earnings call highlights several concerns: delayed revenue growth until 2027, dependency on OEM partnerships, and persistent financial losses. Despite a slight improvement in operating loss, the increase in adjusted EBITDA loss raises red flags. The Q&A section reveals further delays due to global economic shifts and NRE timing, impacting revenue guidance. No positive catalysts like partnerships or optimistic guidance were noted. Given these factors, a negative sentiment is justified, predicting a stock price decline of -2% to -8%.